• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用一种减毒活的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)候选疫苗进行单剂量鼻内接种可促进保护性粘膜和全身免疫。

A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity.

作者信息

Adam Awadalkareem, Kalveram Birte, Chen John Yun-Chung, Yeung Jason, Rodriguez Leslie, Singh Ankita, Shi Pei-Yong, Xie Xuping, Wang Tian

机构信息

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.

Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA.

出版信息

NPJ Vaccines. 2023 Oct 20;8(1):160. doi: 10.1038/s41541-023-00753-4.

DOI:10.1038/s41541-023-00753-4
PMID:37863935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10589337/
Abstract

An attenuated SARS-CoV-2 virus with modified viral transcriptional regulatory sequences and deletion of open-reading frames 3, 6, 7 and 8 (∆3678) was previously reported to protect hamsters from SARS-CoV-2 infection and transmission. Here we report that a single-dose intranasal vaccination of ∆3678 protects K18-hACE2 mice from wild-type or variant SARS-CoV-2 challenge. Compared with wild-type virus infection, the ∆3678 vaccination induces equivalent or higher levels of lung and systemic T cell, B cell, IgA, and IgG responses. The results suggest ∆3678 as an attractive mucosal vaccine candidate to boost pulmonary immunity against SARS-CoV-2.

摘要

先前有报道称,一种具有修饰的病毒转录调控序列且缺失开放阅读框3、6、7和8(∆3678)的减毒严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒可保护仓鼠免受SARS-CoV-2感染和传播。在此,我们报告单剂量鼻内接种∆3678可保护K18-hACE2小鼠免受野生型或变异型SARS-CoV-2攻击。与野生型病毒感染相比,∆3678疫苗接种诱导的肺和全身T细胞、B细胞、IgA和IgG反应水平相当或更高。结果表明,∆3678是一种有吸引力的黏膜疫苗候选物,可增强针对SARS-CoV-2的肺部免疫力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/10589337/f5dd0ef75083/41541_2023_753_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/10589337/1781566e68f8/41541_2023_753_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/10589337/f5dd0ef75083/41541_2023_753_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/10589337/1781566e68f8/41541_2023_753_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/10589337/f5dd0ef75083/41541_2023_753_Fig2_HTML.jpg

相似文献

1
A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity.用一种减毒活的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)候选疫苗进行单剂量鼻内接种可促进保护性粘膜和全身免疫。
NPJ Vaccines. 2023 Oct 20;8(1):160. doi: 10.1038/s41541-023-00753-4.
2
A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity.单剂量鼻内接种一种减毒活新冠病毒候选疫苗可促进保护性黏膜免疫和全身免疫。
bioRxiv. 2023 Apr 18:2023.04.17.537235. doi: 10.1101/2023.04.17.537235.
3
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.鼻内注射慢病毒加强针可增强正在减弱的、由mRNA疫苗诱导产生的、针对肺黏膜的SARS-CoV-2免疫力。
Mol Ther. 2022 Sep 7;30(9):2984-2997. doi: 10.1016/j.ymthe.2022.04.016. Epub 2022 Apr 27.
4
Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.鼻内给予一剂基于 MVA 的 COVID-19 候选疫苗可诱导局部和全身免疫应答,并可保护小鼠免受致死性 SARS-CoV-2 感染。
Front Immunol. 2022 Sep 12;13:995235. doi: 10.3389/fimmu.2022.995235. eCollection 2022.
5
Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.鼻腔接种基于 MVA 的疫苗可诱导 IgA 并保护 hACE2 小鼠的呼吸道免受 SARS-CoV-2 感染。
Proc Natl Acad Sci U S A. 2022 Jun 14;119(24):e2202069119. doi: 10.1073/pnas.2202069119. Epub 2022 Jun 9.
6
Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.鼻腔内接种用 BECC470 佐剂的 VLP-RBD 疫苗可在 K18-hACE2 小鼠中诱导针对德尔塔 SARS-CoV-2 挑战的免疫。
Vaccine. 2023 Jul 31;41(34):5003-5017. doi: 10.1016/j.vaccine.2023.06.080. Epub 2023 Jun 28.
7
Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge.单剂量鼻内给予AdCOVID可引发针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的全身和黏膜免疫,并完全保护小鼠免受致死性攻击。
Vaccines (Basel). 2021 Aug 9;9(8):881. doi: 10.3390/vaccines9080881.
8
An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.一种基于鼻腔内的 OMV 疫苗可诱导针对 SARS-CoV-2 感染的高黏膜和全身保护免疫。
Front Immunol. 2021 Dec 17;12:781280. doi: 10.3389/fimmu.2021.781280. eCollection 2021.
9
Induction of Superior Systemic and Mucosal Protective Immunity to SARS-CoV-2 by Nasal Administration of a VSV-ΔG-Spike Vaccine.通过鼻内接种VSV-ΔG-刺突疫苗诱导对SARS-CoV-2的全身和黏膜保护性免疫
Vaccines (Basel). 2024 May 1;12(5):491. doi: 10.3390/vaccines12050491.
10
Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.鼻腔内递送 MVA 载体疫苗可在啮齿动物中诱导针对 SARS-CoV-2 的有效肺部免疫。
Front Immunol. 2021 Nov 11;12:772240. doi: 10.3389/fimmu.2021.772240. eCollection 2021.

引用本文的文献

1
Live attenuated SARS-CoV-2 vaccine OTS-228 demonstrates efficacy, safety, and stability in preclinical model.减毒活新冠病毒疫苗OTS-228在临床前模型中显示出有效性、安全性和稳定性。
NPJ Vaccines. 2025 May 23;10(1):104. doi: 10.1038/s41541-025-01165-2.
2
Rapid In Vivo Screening of Monoclonal Antibody Cocktails Using Hydrodynamic Delivery of DNA-Encoded Modified Antibodies.利用DNA编码修饰抗体的流体动力学递送对单克隆抗体鸡尾酒进行快速体内筛选。
Biomedicines. 2025 Mar 5;13(3):637. doi: 10.3390/biomedicines13030637.
3
Meeting report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20-24, 2024, organized by the International Society for Antiviral Research.

本文引用的文献

1
Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages.奥密克戎亚谱系的交叉中和与病毒适应性。
Emerg Microbes Infect. 2023 Dec;12(1):e2161422. doi: 10.1080/22221751.2022.2161422.
2
Lung tissue-resident memory T cells: the gatekeeper to respiratory viral (re)-infection.肺组织驻留记忆 T 细胞:呼吸道病毒(再)感染的守门员。
Curr Opin Immunol. 2023 Feb;80:102278. doi: 10.1016/j.coi.2022.102278. Epub 2022 Dec 22.
3
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.
由国际抗病毒研究学会组织的第37届国际抗病毒研究会议会议报告,于2024年5月20日至24日在澳大利亚黄金海岸召开。
Antiviral Res. 2024 Dec;232:106037. doi: 10.1016/j.antiviral.2024.106037. Epub 2024 Nov 13.
4
Intranasal Administration of Recombinant Newcastle Disease Virus Expressing SARS-CoV-2 Spike Protein Protects hACE2 TG Mice against Lethal SARS-CoV-2 Infection.经鼻给药表达 SARS-CoV-2 刺突蛋白的重组新城疫病毒可保护 hACE2 转基因小鼠免受致死性 SARS-CoV-2 感染。
Vaccines (Basel). 2024 Aug 16;12(8):921. doi: 10.3390/vaccines12080921.
5
A murine model of post-acute neurological sequelae following SARS-CoV-2 variant infection.SARS-CoV-2 变异感染后急性神经系统后遗症的小鼠模型。
Front Immunol. 2024 May 3;15:1384516. doi: 10.3389/fimmu.2024.1384516. eCollection 2024.
原始mRNA疫苗或BA.5二价加强针 对SARS-CoV-2奥密克戎BA.2.75.2、BQ.1.1和XBB.1的中和作用较低。
Nat Med. 2023 Feb;29(2):344-347. doi: 10.1038/s41591-022-02162-x. Epub 2022 Dec 6.
4
A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions.一种带有辅助蛋白缺失的活减 SARS-CoV-2 疫苗候选物。
Nat Commun. 2022 Jul 27;13(1):4337. doi: 10.1038/s41467-022-31930-z.
5
Factors Limiting the Translatability of Rodent Model-Based Intranasal Vaccine Research to Humans.限制基于啮齿动物模型的鼻内疫苗研究向人类转化的因素。
AAPS PharmSciTech. 2022 Jul 12;23(6):191. doi: 10.1208/s12249-022-02330-9.
6
SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.SARS-CoV-2 引起人类 ACE2 基因敲入小鼠肺部感染但不引起严重疾病。
J Virol. 2022 Jan 12;96(1):e0151121. doi: 10.1128/JVI.01511-21. Epub 2021 Oct 20.
7
Scent of a vaccine.疫苗的气味。
Science. 2021 Jul 23;373(6553):397-399. doi: 10.1126/science.abg9857.
8
Editorial: Revised World Health Organization (WHO) Terminology for Variants of Concern and Variants of Interest of SARS-CoV-2.社论:世界卫生组织(WHO)修订的关于 SARS-CoV-2 的关注变体和感兴趣变体的术语。
Med Sci Monit. 2021 Jun 21;27:e933622. doi: 10.12659/MSM.933622.
9
Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.鼻腔内给予重组 RBD 疫苗可诱导小鼠对 SARS-CoV-2 产生保护性免疫。
Vaccine. 2021 Apr 15;39(16):2280-2287. doi: 10.1016/j.vaccine.2021.03.006. Epub 2021 Mar 5.
10
COVID-19 vaccines: modes of immune activation and future challenges.COVID-19 疫苗:免疫激活模式和未来挑战。
Nat Rev Immunol. 2021 Apr;21(4):195-197. doi: 10.1038/s41577-021-00526-x.